China Grand Pharmaceutical and Healthcare Holdings Ltd. (01093.HK): GLP-1/GIP receptor biased agonist dual action peptide injection has been approved for clinical trials in the United States.

Zhtng Financial APP news, CSPC Pharmaceutical Group (01093.HK) announced that the GLP-1/GIP receptor biased agonist dual-peptide injection (SYH2069 injection) developed by the group has been approved by the US Food and Drug Administration (FDA) and can conduct clinical trials in the United States.